Humanigen - Lenzilumab Being Studied as a Potential First Treatment in Thirty Years with a Novel Mechanism of Action for Chronic Myelomonocytic Leukemia (CMML), an Orphan Form of Leukemia ...

Lenzilumab's mechanism of action has already been de-risked to some degree in COVID-19-associated respiratory distress by clinical trials conducted with other GM-CSF blockade antibodies.

Lenzilumab is a late clinical-stage, monoclonal antibody targeting GM-CSF, a pro-inflammatory cytokine up-regulated in the serum of COVID-19 patients2.

Humanigen Inc (OTCQB:HGEN) presented findings Tuesday showing that a cohort of 12 patients with coronavirus-associated pneumonia treated with its drug lenzilumab had a mean recovery time nearly twice ...

Having previously published data demonstrating the ability of lenzilumab to prevent and/or treat cytokine storm, Humanigen believes lenzilumab may be synergistic in the treatment of patients with ...

The Food and Drug Administration (FDA) has declined the Emergency Use Authorization request for lenzilumab for the treatment of hospitalized patients with COVID-19.

Positive interim results were announced from a phase 3 study of lenzilumab for COVID-19 pneumonia.

Humanigen's monoclonal antibody lenzilumab significantly increased survival without the use of mechanical ventilation among hospitalized COVID-19 patients, according to a study published Dec. 1 in ...

Data suggest potential therapeutic role for nomacopan in exacerbations in severe lung conditions such as COPD and COVID pneumonia NEW YORK and LONDON, Dec. 01, 2021 (GLOBE NEWSWIRE) -- Akari ...

“Lenzilumab is one of the few Phase 3 treatment options in development for COVID-19, and we believe that its mechanism of action as an immunomodulator could work very nicely with remdesivir and ...

Humanigen's monoclonal antibody lenzilumab significantly increased survival without the use of mechanical ventilation among hospitalized COVID-19 patients, according to a study published Dec. 1 in ...